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Abstract: Calcium electroporation (Ca-EP) is a new anticancer treatment providing similar features
to electrochemotherapy (ECT). The aim of our study is to compare the efficacy of Ca-EP with
bleomycin-based ECT. This double-blinded randomized controlled phase II study was conducted at
the Medical University of Szeged, Hungary. During this once only treatment up to ten measurable
cutaneous metastases per patient were separately block randomized for intratumoral delivery of
either calcium or bleomycin, which was followed by reversible electroporation. Tumour response was
evaluated clinically and histologically six months after treatment. (ClinicalTrials.gov: NCT03628417,
closed). Seven patients with 44 metastases (34 from malignant melanoma, 10 from breast cancer)
were included in the study. Eleven metastases were taken for biopsies, and 33 metastases were
randomised and treated once. The objective response rates were 33% (6/18) for Ca-EP and 53%
(8/15) for bleomycin-based ECT, with 22% (4/18) and 40% (6/15) complete response rates, respectively.
The CR was confirmed histologically in both arms. Serious adverse events were not registered.
Ulceration and hyperpigmentation, both CTCA criteria grade I side effects, were observed more
frequently after bleomycin-based ECT than for Ca-EP. Ca-EP was non-inferior to ECT, therefore,
it should be considered as a feasible, effective and safe treatment option.
Keywords: calcium electroporation; bleomycin-based electrochemotherapy; cutaneous metastases;
melanoma malignum; breast cancer; randomization; biopsy; non-inferiority
1. Introduction
Bleomycin-based ECT is a widely used method for the treatment of cutaneous tumours from all
histologies [1–6]. During ECT, a chemotherapeutic drug, usually bleomycin, is electroporated into the
Cancers 2020, 12, 179; doi:10.3390/cancers12010179 www.mdpi.com/journal/cancers
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tumour cells, resulting in an increased cytotoxic effect. A recent meta-analysis of ECT in a palliative
setting found a complete response (CR) rate of 46.6% and objective response rates (ORR) of 82.2%,
regardless of the tumour type. Beyond its effectiveness, ECT is a repeatable and minimally invasive
intervention that reduces symptom burden [7].
With the goal of reducing the risk of possible adverse events, the chemotherapeutic drug
(bleomycin) is replaced with calcium in calcium electroporation (Ca-EP). Notably, calcium might be
an effective option in cases where the administration of a chemotherapeutic drug is contraindicated.
It was also expected that the use of Ca-EP will simplify the procedure and lower the treatment cost.
The mechanism of action and the anticancer efficacy of Ca-EP have been confirmed in preclinical
studies. During Ca-EP treatment, electroporation increases intracellular calcium concentration, leading
to increased ATP consumption. Additionally, the treatment leads to further loss of ATP production
by opening permeability transition pores in mitochondrial membranes. This ATP depletion, together
with other cellular effects, causes cell death [8].
The features of Ca-EP are very similar to ECT: they are both selective to tumour cell, the same
pulsing conditions can be used for both procedures, and both have an anti-angiogenic effect in vitro
and in vivo on both normal and tumour blood vessels [9,10]. It has also been demonstrated that Ca-EP
initiates a systemic immune response. Thus, Ca-EP has the potential to replace bleomycin with calcium
in electroporation treatments.
The first clinical trial of Ca-EP in humans was published recently [11]. The method was used with
seven patients (six with breast cancer, one with malignant melanoma), and safety and non-inferiority
in comparison with bleomycin-based ECT was proven.
To provide additional evidence on the efficacy and safety of Ca-EP, we decided to conduct a
clinical trial. The aim of this study is to evaluate safety and efficacy of Ca-EP and to compare it with
bleomycin-based ECT for cutaneous metastases.
2. Materials and Methods
This non-inferiority, phase II, double blinded, randomized confirmatory study investigated the
efficacy of Ca-EP in comparison with the currently approved bleomycin-based ECT procedure for the
treatment of cutaneous metastases. The study protocol was authorized by the Health Registration
and Training Centre on 3 May 2016 and registered under the case number 032104/2016/OTIG. It was
approved by the national and institutional ethical review boards (SZTE Regional Institutional Ethics
Committee (23 May 2016, license no. 3806; registry no. 98/2016-SZTE). Patients provided written
informed consent before enrolment.
The primary endpoint of the study was to compare the tumour response of cutaneous metastases
after application of Ca-EP and ECT with the administration of intratumoral bleomycin. Tumour
response was evaluated similar to response evaluation criteria in solid tumours (RECIST), v1.1,
on each treated metastasis by clinical examination and digital photo documentation before and
after treatment. The secondary endpoint was to evaluate and grade the toxicity of Ca-EP similar to
Common Terminology Criteria for Adverse Events (CTCAE), version 4.0. The third endpoint was the
measurement of the maximum safe and effective delivery of current to metastases using Ca-EP and
bleomycin-based ECT.
Patients enrolled in the study had at least one histologically confirmed metastasis of 0.5 to 3 cm
in size that was accessible to electroporation. A maximum of 10 cutaneous metastases per patient
was included in the trial. Depending on the number of metastases present on the patient, one to
six metastases were randomized into one of the two treatments and to the right or the left arm for
evaluating response. Calcium was administered intratumorally to tumour(s) of one arm and bleomycin
to the other and administration was immediately followed by electroporation of tumours on both arms.
Patient inclusion criteria were as follows: age >18 years, World Health Organization (WHO)
performance status ≤2, life expectancy more than 3 months, platelet count ≥50 billion/L, international
normalised ratio (INR) <1.5, and a period of more than 2 weeks of without treatment [12]. Only medical
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cancer treatments (endocrine treatment, targeted treatment and radiotherapy to another area) were
allowed. If there was no regression of cutaneous metastases, the continuation of vinorelbine,
capecitabine or paclitaxel therapies were allowed. Patients were excluded from the trial if they
had severe allergic reactions associated with bleomycin or if they previously received a dose of
bleomycin that was more than 200,000 units/m2. Pregnancy and lactation were also reasons for
exclusion. Previously irradiated cutaneous metastases and concomitant treatments were recorded.
The intervention was performed after oncological recommendation.
2.1. Randomization and Blinding
A clinical pharmacologist, who was independent of all the parties concerned with the study, was
in charge of randomisation and kept the randomisation list secure, with the task of providing limited
access only in case of emergency. The numbered metastases in each patient were block randomised 1:1
separately into the two treatment arms with the nQuery Adviser 7.0 computer program. The drugs to
be given for each metastasis were prepared and labelled by a clinical pharmacologist. There was no
need to cover the content of the ready syringes, as both bleomycin and calcium-chloride are colourless.
2.2. Procedure
The concentration of calcium chloride was estimated to be 220 mmol/L (9 mg/mL) from preclinical
studies [9,12–14] and of bleomycin was 1000 IU/mL.
The volume to be injected was calculated according to the volume of the tumour. The drug
volume for large tumours (>0.5 cm3) was 0.5 mL/cm3, while for small tumours (<0.5 cm3) the volume
was amended to 1 mL/cm3. Tumour volume was calculated as ab2pi/6, where a = longest diameter,
b = longest diameter perpendicular to a.
Electric pulses were generated using a Cliniporator device (IGEA, Carpy, Italy) according to
the standard operating procedures of the electrochemotherapy (ESOPE) guidelines. Linear needle
electrodes (8 pulses of 400 V and 1000 V/cm, of 0.1 ms duration, at a frequency of 5 kHz) and hexagonal
needle electrodes (4 pulses of 730 V and 910 V/cm, of 0.1 ms duration, at a frequency of 5 kHz) were
used according to the tumour size and location. The anaesthesia during the procedure was either local
or general, as planned during the consultation between the physician and the patient. Lidocaine with
epinephrine was used as local anaesthetic and was injected in a square around the nodule. Changes in
the response to anaesthesia were not observed.
Patients underwent the treatment once and were followed for 12 months with scheduled visits (7,
15, 30, 60, 90, 180 and 360 days after the treatment session).
At each follow up visit, the tumour response was evaluated clinically, and photos were taken.
Response was categorised according to criteria similar to RECIST guidelines 1.1 as follows: complete
response (CR), disappearance of all target lesions; partial response (PR), at least a 30% decrease in
the sum of the longest diameter of target lesions; stabile disease (SD), neither sufficient shrinkage to
qualify for PR nor sufficient increase to qualify for progression; and progression of the disease (PD),
at least a 20% increase in the sum of the longest diameter of target lesions [15].
The randomization code was revealed 6 months after treatment and biopsies were taken from
both calcium- and bleomycin-treated lesions. All biopsies were analysed by a histopathologist for the
amount of tumour tissue, inflammation, fibrosis and necrosis.
Safety was evaluated with physical examinations and blood tests before and after treatment.
Quality of life (QOL) score (0–100%) was also evaluated before and after the treatment. A numeric
rating scale (NRS) (0–10) was used for assessing pain [16]. The Common Toxicity Criteria for Adverse
Events, version 4.0, was used to register possible adverse events [17].
All Participants Assessed the Primary and Safety Analyses
The statistical analyses were performed using IBM SPSS, v24, software and R statistical program.
Tumour response was analysed using Fisher’s exact test on objective response 6 months after treatment,
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Mann-Whitney test was used to measure the difference in delivered current between calcium-EP and
bleomycin-based ECT, and the 2-sided 95% CI was used to measure the difference in outcome between
the two groups [18]. For dimensioning the required number of cutaneous metastases, a non-inferiority
study analysis was used: calculated with a significance level of 0.05 and a power of 80%, the results
indicated that a minimum of 28 evaluable tumours were needed [19]. Taking into consideration the
results of the previous clinical trial for the treatment of Ca-EP on cutaneous metastases as well as
the basis of preclinical studies, a 20% non-inferiority margin was preset to detect a clinical difference
between the two treatment arms.
3. Results
Seven patients (5 females, 2 males) with a total of 44 cutaneous metastases (34 from melanoma
malignum and 10 from breast cancer) were enrolled in the clinical trial between October 2016 and June
2018 (Figure 1). Six patients had cutaneous metastases of malignant melanoma, localized on the lower
extremity and one patient had metastases of breast cancer, localized on the trunk (Table 1). The patients
median age was 73 years (Interquartile range: IQR = 21). Thirty-three metastases were randomized
into the two treatment arms (left or right) of the study and were evaluated for clinical response,
whereas 11 lesions were taken as biopsies (Figure 2). Eighteen of the randomized metastases were
treated with Ca-EP (15 melanoma malignum cutan metastases, 3 breast cancer metastases) and 15 with
bleomycin-based ECT (12 melanoma malignum cutan metastases, 3 breast cancer metastases). Six (18%)
of the 33 randomized cutaneous metastases were located on a previously irradiated area (2 lesions were
treated with Ca-EP, and 4 lesions with bleomycin-based ECT). According to the 33 response-evaluated
metastases, the median was 7 mm (IQR = 5) of the largest diameters. The median injected volume for
Ca-EP was 0.0855 mL (IQR = 0.1924), and 0.132 mL (IQR = 0.27) for bleomycin-based ECT (Table 2).
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Table 1. Baseline demographic and clinical characteristics of the patients.
Patient SexAge (year)
Primary Tumour
Characteristics
Location of Cutan
Metastases
Number of
Metastases
Included/Evaluated
Years Since
Diagnosis Previous Therapy
Concomitant
Treatment
1. Male76 pT3b, ALM, BRAF-WT lower extr. 1/1 1 - -
2. Female62
Breast: HER2-, ER+,
PgR+ trunk 10/6 5.6
Epi-txt, Letrozole,
mTORi Letrozole
3. Female83
pT3b, NM, BRAF-WT,
satellite met.
Ing. sentinel: pos.
BD: negative
lower extr. 9/6 7 adj. IFN,radiotherapy, ECT -
4. Female49 pT3b, SSM lower extr. 3/3 2 adj. IFN -
5. Female83
pT3a, ALM, BRAF-WT
Ing. sentinel: neg. lower extr. 10/6 4.5 ECT -
6. Female64 pT2a, SSM, BRAF-WT lower extr. 6/6 2.75 - -
7. Male73 pT3a, ALM, BRAF-WT lower extr. 5/5 3.8
adj. IFN,
radiotherapy -
Total
5 Females, 2 Males
mean: 70
(σ = 11.4891)
MM: 6, BRAF-WT: 5/6
Breast: 1
6 lower extr.
1 trunk 44/33
Mean
3.8
(σ = 1.9329)
various
MM: malignant melanoma; ALM: acral lentiginous melanoma; extr.: extremity; NM: nodular melanoma; SSM: superficial spreading melanoma; BD: block dissection, BRAF WT: BRAF wild
type; IFN: interferon; σ: standard deviation.
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Table 2. Results of the current study in comparison with the study published in 2018.
Treatment Arm
Calcium-Electroporation Bleomycin-Based Electrochemotherapy
Current Study 2018 Study Total Current Study 2018 Study Total
Lesion characteristics
Tumour size
Median of the largest diameter, mm 6.5 (5–30) 9.5 (5–18) 7 (5–25) 11 (4–25)
Tumour type
Malignant melanoma 15 1 16 12 1 13
Breast cancer 3 17 20 3 18 21
Previously irradiated lesions, n 2 8 10 4 7 11
Location
Lower extremity 15 4 19 12 4 16
Trunk 3 14 17 0 15 15
Upper extremity 0 0 0 3 0 3
Treatment
Median doses (range), mL 0.085 (0.042–3.14) 0.24(0.03–1.21)
0.132
(0.065–0.475)
0.21
(0.03–0.55)
Median delivered current (range), A 3.85 (1.4–9) 3.4 (0.9–8.2) 4 (1.4–6.5) 2.8 (1–9.6)
Median delivered current with linear
electrodes (range), A 4 (2.25–9) 3.4 (0.9–8.3) 5.05 (4–6.1) 2.8 (1–9.6)
Median delivered current with hexagonal
electrodes (range), A 2.5 (1.4–4.2) NA 2.75 (1.4–3.6) NA
Median number of applications (range), n 1 (1–6) 3 (1–7) 1 (1–3) 3 (1–7)
Electrodes
Linear 39% (7) 100% (18) 33% (5) 100% (19)
Response (CR) for linear electrode subgroup 14% (1) 66% (12) 0 68% (13)
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Table 2. Cont.
Treatment Arm
Calcium-Electroporation Bleomycin-Based Electrochemotherapy
Current Study 2018 Study Total Current Study 2018 Study Total
Lesion characteristics
Hexagonal 61% (11) 0 67% (10) 0
Response (CR) for hexagonal electrodes
subgroup 27% (3) NA 60% (6) NA
Response
Complete response, percent (n) 4 12 44.44% (16) 6 13 55.88% (19)
Partial response, percent (n) 2 1 8.33% (3) 2 3 14.7% (5)
Stable disease, percent (n) 6 3 25% (9) 5 0 14.7% (5)
Progressive disease, percent (n) 6 2 22.22% (8) 2 3 14.7% (5)
Adverse events
Ulceration, percent (n) 2 7 25% (9) 3 13 47.05% (16)
Itch, percent (n) 0 1 2.77% (1) 0 5 14.7% (5)
Hyperpigmentation, percent (n) 2 0 5.55% (2) 6 5 32.35% (11)
Exuding, percent (n) 0 2 5.55% (2) 0 2 5.88% (2)
Current study: Evaluation of calcium electroporation for the treatment of cutaneous metastases; a double blinded randomized controlled phase II trial, Department of Dermatology and
Allergology, University of Szeged (ClinicalTrials.gov: NCT03628417). 2018 study: Calcium electroporation for treatment of cutaneous metastases; a randomized double-blinded phase II
study, comparing the effect of calcium electroporation with electrochemotherapy, Denmark [11].
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Figure 2. Histology from biopsies before and 7 days after treatment. Biopsies before and one week
after treatment. (A–C) Patient nr. 5 with MM. A: Pre-treatment biopsy: Extensive tumour infiltration,
mild fibrosis, moderate lymphocytic inflammation, no necrosis. The tumour cells show diffuse MelanA
positivity. (B) Day 7. Post-treatment with Ca-EP: Partly ulcerated skin, moderate tumour infiltration and
fibrosis, mild inflammation, no necrosis. Only scattered MelanA positive tumour cells. (C) Day 7. Post
treatment with bleomycin-based ECT: Partly fragmented, ulcerated skin with pseudoepitheliomatous
hyperplasia of the epidermis, moderate fibrosis and inflammation, no necrosis. Focal MM nests with
MelanA positivity. (D–F) Patient nr. 2 with breast cancer. (D) Pre-treatment biopsy: Extensive breast
cancer infiltration without fibrosis, inflammation and necrosis. The tumour cells are CKAE1/AE3
positive. (E) Day 7. Post-treatment with Ca-EP: Focal tumour infiltration, very mild inflammation no
fibrosis or necrosis. (F) Day 7. Post treatment with bleomycin-based ECT: Dispersed tumour cells with
CKAE1/AE3 positivity, mild inflammation, no fibrosis or necrosis. MM: malignant melanoma, CK:
cytokeratin. Histological photos: digital scanning with magnification approximately 5–20×.
Four of the procedures were conducted under local, and three of them under general anaesthesia.
Hexagonal needle electrodes were used for electroporation of 21 metastases, (63.6%), whereas linear
electrodes were used for 12 lesions (36.4%). Of the 18 lesions receiving Ca-EP, 11 were treated with
hexagonal (61.1%) and 7 with linear electrodes (38.9%), respectively. Of the 15 lesions receiving
bleomycin-based ECT, 10 were treated with hexagonal electrodes (66.7%), and 5 with linear electrodes
(33.3%).
3.1. Tumor Response
The ORR for Ca-EP was 33% (CR = 22%; PR = 11%) and for bleomycin-based ECT was 53%
(CR = 40%; PR = 13%) (Figure 3). The difference was not significant neither in OR (p = 0.30) nor in CR
(p = 0.45) between Ca-EP and bleomycin-based ECT. After 6 months, 33% (6 of 18) metastases treated
with c lcium, and 13% (2 of 15) metastases treated with bleomycin had progressed. The two-sided
95% CI fo the outcome difference between the two groups was −13.3%–53.3%. There was no
significant difference i response between previously irradiated and non-irradiated lesions (p = 0.37).
Six months after treatment, the randomization code was revealed, and 6 biopsies (3 from Ca-EP, 3
from bleomycin-treated lesions) taken from the 13 tumours exhibited a clinically CR. For 5 of these 6
biopsies, a CR was confirmed by histology (Figure 4). No tumour cells were identified in the 3 lesions
treated with Ca-EP and in 2 of the lesions treated with bleomycin-based ECT.
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Figure 3. Change in tumour size over time. Metastases were treated at day = 0 with either i.t. calcium
and or i.t. bleomycin in a randomized double-blinded study design. Patients received only one
treatment and response was evaluated 6 months after treatment, after the randomization code was
revealed. Change in size over time; the graph illustrates the percent change in tumour size recorded
6 months after treatment. The two non-measurable metastases treated with calcium-chloride and
bleomycin were irradiated, and are not included in the graph, but were included in the response
analysis as PD.
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Figure 4. istologically confir e co plete re ission 6 onths after a- P. u our cells ere not
identified 6 onths after Ca-EP neither in malignant melanoma (A) nor in breast cancer metastases (B).
A: patient no 3, Ca-EP treated clinically CR melanoma malignum cutaneous metastasis. B: patient no 2,
Ca-EP treated clinically CR breast cancer cutaneous metastasis. Histological photos: digital scanning
with low magnification.
Regarding tumour response and the type of electrode, we observed differences between the
two treatment arms that because of the small sample size was statistically not significant. The ORRs
obtained with Ca-EP cutaneous metastases were higher for linear electrodes (42.8%, 3/7) than for
hexagonal electrodes (27.3%, 3/11) (p = 0.63). Of the tumours that were categorized as PD, 45.45% (5/11)
were treated with hexagonal and 14.29% (1/7) with linear electrodes (p = 0.32). The opposite trend was
observed with bleomycin-based ECT. The ORR was 70% (7/10) with hexagonal and 20% (1/5) with
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linear electrodes (p = 0.12). Of the tumours that were categorized as PD, 10% (1/10) were treated with
hexagonal and 20% (1/5) with linear electrodes (p = 1).
Six patients had long-term follow-up over a mean of 29 months (standard deviation: σ = 6.8232).
One patient died 11 months after the study treatment session because of the progression of another
primary tumour and two additional patients died 26 and 27 months after treatment because of a hip
fracture and progression of the melanoma, respectively. None of the cutaneous metastases categorized
as CR relapsed during the 1-year follow-up period.
3.2. Adverse Events
Serious adverse events were not observed. Ulceration and hyperpigmentation, both CTCA criteria
grade I side effects, were seen after Ca-EP in two metastases each (2/18, 11%). After bleomycin-based
ECT, ulceration was observed in 20% (3/15) and hyperpigmentation in 40% of the treated lesions (6/15)
(Figure 5). The median NRS score before treatment was 2 (IQR = 2). Immediately after treatment
the median NRS score was 2 (IQR = 9), 3 patients reported no pain (NRS: 0), 1 patient reported mild
pain (NRS: 1–3) and 1 patient moderate pain (NRS: 4–6). Two patients, both having more than six
metastases and who underwent biopsies, reported severe pain (NRS: 9–10). Six months after treatment
the median NRS score was 2 (IQR = 4), with medium values of 2.5 (σ = 3.2016) for patients treated
with Ca-EP and 4.5 (σ = 2.2913) for patients treated with ECT.
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Six months after treatment, the QOL scores were equal to or higher than before treatment.
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patients did not report a change in their quality of life during the 6 months after treatment. All 7
patients reported they would agree to repeat the treatment if necessary.
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3.3. Delivered Current
There was no significant difference in the measured delivered current neither between the
two treatment arms (p = 0.956) nor in non-irradiated metastases compared to irradiated metastases
(p = 0.911). The median delivered current was 3.85 A (IQR = 3.75) in metastases treated with calcium
and 4 A (IQR = 2.4375) with bleomycin. The median delivered current in metastases located in
non-irradiated skin was 3.85 A (IQR = 3.45) and 3.95 A (IQR = 1.525) in metastases from previously
irradiated skin. A total of 30 applications were used with a median value of 1 (range 1–6, IQR = 1) to
the 18 randomized lesions treated with Ca-EP, and 22 applications with a median value of 1 (range 1–3,
IQR = 1) to the 15 cutaneous metastases treated with bleomycin-based ECT. The median delivered
current measured with linear electrodes in the two treatment arms (Ca-EP and bleomycin-based ECT)
was 5 A (range 2.25–6.1, IQR = 2.1; 31 applications) and 2.5 A (range 1.4–4.2, IQR = 1.6; 21 applications)
with hexagonal electrodes. In the Ca-EP arm the median delivered current was 2·5 A (range 1.4–4.2,
IQR = 1.5; 11 applications) with hexagonal and 4 A (range 2.25–9, IQR = 3.5; 19 applications) with linear
electrodes. In the bleomycin-based ECT group the median delivered current was 2.75 A (range 1.4–3.6,
IQR = 1.7125; 10 applications) with hexagonal and 5.05 (range 4–6.1, IQR = 1.325; 12 applications) with
linear electrodes (Table 2).
3.4. Discussion
Ca-EP is a novel anticancer treatment that has been used successfully with tumours exhibiting
various histologies. Preclinical studies provided the first support for the efficacy across cancer
histologies, as well as an explanation of the mechanisms of action [11,13,14,20–27]. The results of the
first clinical trials suggested that Ca-EP is safe and efficient at the local level for tumours of different
types, including cutaneous metastases from breast cancer and malignant melanoma and recurrent
head and neck cancer [11,20]. Moreover, a case report showed that Ca-EP is able to initiate a systemic
immune response and target untreated metastases in a patient suffering from malignant melanoma [28].
In the Ca-EP procedure, no chemotherapeutic drug is administered to the patient, and, therefore it is
ideal in cases when chemotherapy is contradicted (e.g., severe lung function impairment, pregnancy
etc.). Ca-EP is a simple and inexpensive cancer treatment and can lead to good cosmetic outcome.
We were encouraged to implement the second trial with Ca-EP on cutaneous metastases by the
results of the first clinical studies and by the possibility that Ca-EP can be used in cases when bleomycin
cannot be administered.
In our study, which included six patients with malignant melanoma and one patient with breast
cancer, we demonstrated that Ca-EP is safe and effective in the treatment of small cutaneous metastases.
Importantly, the CR seen clinically after Ca-EP was confirmed in our study by histology. The ORR for
Ca-EP was lower (ORR = 33%, CR = 22%) than for bleomycin-based ECT (ORR = 53%, CR = 40%),
but the differences were not significant for OR (p = 0.30) and for CR (p = 0.45). Our preset criteria
for the non-inferiority for Ca-EP was proven. The first clinical trial performed in Denmark included
seven patients: six patients with cutaneous metastases of breast cancer and one patient with malignant
melanoma [11]. The results from this study had a similar tendency toward higher ORR and no
significant difference between Ca-EP, 72% (with 66% CR), and ECT, 84% (with 68% CR). The first trial
also proved non-inferiority for Ca-EP, and only mild adverse events were observed for both treatments,
including ulcers in the treated area, similarly to our study. The higher response rates achieved by the
Danish study could be explained by the different histotypes of the treated cutaneous metastases and
also with the use of different electrodes. We have treated mainly malignant melanoma metastases
(81.8%, n = 27), whereas the number of melanoma metastases was small (5.4%, n = 2) in the Danish
study. The primary tumour characteristics of our study show that 89% (24/27) of the response evaluated
melanoma metastases were BRAF-WT (wild-type or non-mutated). A recent study revealed that
bleomycin-based ECT is more effective on BRAF mutated malignant melanoma cells in comparison
with WT (non-mutated) melanoma cells [29]. These results could account for the lower response rates
on both arms of the current study and require further investigation.
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The other difference between the two trials were the electrodes used; only linear electrodes were
used in the Danish, where as our study used mainly (63.6%) hexagonal electrodes. It is known that the
electric field distribution is different between the linear (which have a smaller diameter) and hexagonal
electrodes. Therefore, with linear electrodes field distribution is much more symmetrical with less
cold spots. [30,31] Although a significant difference was not detected because of the small number of
events, Ca-EP was more effective in our trial with linear electrodes, (p = 0.30). In preclinical studies
significantly decreased ATP level and cell viability were observed by increasing the electric field from
0.8 to 1.0 kV/cm during Ca-EP [9,23]. These findings could explain the observed difference as the
electric field was 1000 V/cm with the use of linear and 910 V/cm with hexagonal electrodes. Because of
the small sample size of the current trial, further studies are needed to fully uncover the question.
There was no significant difference in the measured delivered current between the two treatment
arms in the two finished studies. The difference in conductivity may be more relevant when treating
large tumours.
Only grade I local adverse events were seen in both treatment arms in our study. Both ulceration
and hyperpigmentation were observed more often after bleomycin-based ECT (20% and 40%) than after
Ca-EP (both 11%). Our observations of Ca-EP skin toxicity were similar to those of the previous trial:
only the tumour region was affected by the ulcer, whereas the surrounding normal skin was spared.
In the Danish trial, none of the lesions treated with Ca-EP exhibited altered cutaneous pigmentation,
which might be related to the exclusive use of linear electrodes.
The limitations of our study include a small number of enrolled metastases and the use of
different electrodes.
4. Conclusions
Ca-EP proved to be safe and effective in eradicating tumours, and this conclusion was confirmed
histologically. Our results are in agreement with the results of the first clinical trial on Ca-EP, which
showed that Ca-EP was non-inferior to bleomycin-based ECT, and therefore Ca-EP should be considered
as a feasible treatment for patients with cutaneous metastases for which other chemotherapeutic drugs
are contraindicated.
The configuration of the electrode and the histotype may influence tumour response. Further
studies are needed to establish a strong evidence base in the treatment of cutaneous metastases
with Ca-EP.
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